Forum for Science, Industry and Business
  • Sponsored by:
  • Siemens
  • Siemens
  • Siemens
Search our Site:

Topic (optional):

 

Home Reports Life Sciences Content

Flexible pain relief with morphine-free poppy

next article
23.09.2004

 


Morphine-free poppy


A handful of genes in a morphine free poppy could hold the key to producing improved pain management pharmaceuticals. Norman, the ’no-morphine’ poppy, is superior to morphine producing poppies as it produces thebaine and oripavine – compounds preferred by industry in the manufacture of alternative high value pain-killers.

CSIRO’s Dr Phil Larkin, and The Australian National University’s Anthony Millgate and Dr Barry Pogson have been working with Tasmanian Alkaloids to investigate Norman the morphine-free poppy. "The genes we found behaved differently in Norman compared to standard morphine producing poppies and were consistently associated with the blockage in morphine synthesis and with the accumulation of thebaine and oripavine," Dr Larkin says.

"Understanding the genes responsible for the production of morphine, thebaine and oripavine is an important step in further developing poppies that are tailored to produce alternative pharmaceuticals."

The morphine free poppy variant, TOP1, was first discovered in 1995 by Tasmanian Alkaloids then released as Norman for commercial production in 1997 in Tasmania where it is now widely grown. "Norman created substantial industry growth when there was a surplus of traditional products, such as morphine, allowing us to supply raw materials for the manufacture of other pharmaceutical ingredients," says Tasmanian Alkaloids’ Manager of Agricultural Research, Dr Tony Fist.

Tasmania already grows over 40 per cent of the world’s legal poppy crops and Norman will ensure Tasmania stays an international leader in pharmaceutical development from poppy compounds.

This research is supported by voluntary contributions from industry with matched funding for R&D from the Australian Government through HAL and is a collaboration between CSIRO Plant Industry, The Australian National University, Tasmanian Alkaloids, Institute for Plant Biochemistry (Germany) and the University Halle (Germany).

Sophie Clayton | Source: EurekAlert!
Further information: www.csiro.au

next article

More articles from Life Sciences:

nachricht New beta-blocker to offer hope to heart and lung sufferers
29.08.2008 | University of Nottingham

nachricht Antidepressants Need New Nerve Cells to be Effective
29.08.2008 | UT Southwestern Medical Center

B2B Search

Product / Service
Company / Organisation

Latest News

Internet law made simple

29.08.2008 | Information Technology

Why did the squirrel cross the road?

29.08.2008 | Studies and Analyses

Revealed: The secret of plasma heating

29.08.2008 | Physics and Astronomy